Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough ovarian cancer? drug combo trial begins

NCT ID NCT06964009

Recruiting now Disease control Sponsor: Elizabeth Stover, MD, PhD Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 29 times

Summary

This early-phase study tests a new drug (DT2216) combined with standard chemotherapy (paclitaxel) in 30 people with ovarian cancer that has returned and is resistant to platinum-based treatments. The main goal is to find the safest dose of DT2216 when given with paclitaxel, and to see how well the combination controls the cancer. This is not a cure, but aims to manage the disease and improve treatment options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center (BIDMC)

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

    Contact

  • Brigham and Women's Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER OVARIAN CARCINOMA RECURRENT OVARY CANCER RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA